Welcome to Update+, a short tour around the grounds of investment in the big disruptive trends that are driving business. For November, Investment Analyst Tom Keir runs explains Eli Lilly’s advantage over its large pharmaceutical competitors in making the most of the diabesity opportunity.
This video expands on a presentation given by Chief Investment Officer Alex Pollak several weeks back. Alex’s presentation is available here: https://www.youtube.com/watch?v=b3gr08H7grw&t=0s
Share this Post